Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma (IFFaLCCO)

Rennes University Hospital

Status: Completed

Conditions: Ovarian Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT02297958

2014-A01041-46

Details and patient eligibility

About

Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.

Enrollment: 28 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Pre-Inclusion Criteria:

• Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT)

Inclusion Criteria:

• Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.
• Neo adjuvant chemotherapy

Exclusion Criteria:

• no neo-adjuvant chemotherapy
• no ovarian carcinoma at final pathological analysis
• less than 18 years old.